Search
Close this search box.
Search
Close this search box.

English

2024 Business School Applications Skyrocket amidst Economic Uncertainty

GMAC’s annual survey shows demand growth is five times greater than the pandemic boom RESTON, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) — Across the globe, total applications to graduate business school programs in 2024 increased an impressive 12 percent from 2023 to 2024. This is a sharp reversal from the

2024 Business School Applications Skyrocket amidst Economic Uncertainty

GMAC’s annual survey shows demand growth is five times greater than the pandemic boom RESTON, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) — Across the globe, total applications to graduate business school programs in 2024 increased an impressive 12 percent from 2023 to 2024. This is a sharp reversal from the

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are